ClinicalTrials.gg
CompletedNCT01490632Updated Sep 27, 2019Results posted

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

A Phase 2 interventional study of Placebo and Baricitinib in Psoriasis, Skin Diseases and Skin Diseases, Papulosquamous, sponsored by Eli Lilly and Company. Completed at 35 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
11th of 36
271 · median 181
Started
2011
with 1 other
Phase 2
9 of 36
none open now
Registered
4th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 2, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

03

Conditions studied

  • Psoriasis
  • Skin Diseases
  • Skin Diseases, Papulosquamous

Keywords

  • Moderate
  • Severe
  • Plaque
  • Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study
  • You are a candidate for systemic therapy and/or phototherapy
  • You must have active plaque psoriasis covering at least 12% body surface area
  • You must have Psoriasis Area and Severity Index (PASI) score of at least 12
  • You must have Static Physician's Global Assessment (sPGA) score of at least 3

Exclusion criteria

Exclusion Criteria:

  • You must not have received a biologic agent/monoclonal antibody within 8 weeks prior to entry into the study
  • You must not have prior treatment with an oral Janus kinase (JAK) inhibitor
  • You must not have received a systemic psoriasis (Ps) therapy within 4 weeks prior to entry into the study
  • You must not have received a phototherapy within 4 weeks prior to entry into the study
  • You must not have received a topical Ps therapy with psoralens within 4 weeks prior to entry into the study
  • You must not be pregnant or nursing
  • If female of or a male, and do not agree to use 2 forms of highly effective methods of for at least 28 days following the last dose of product
  • You must not have had symptomatic herpes zoster or herpes simplex infection within 12 weeks or have a history of disseminated/complicated herpes zoster
  • You must not have evidence of active infection, such as fever ≥38.0ºC (100.4ºF)
  • You must not have a history of active , , or (HIV)
  • You must not be and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
  • You must not have known history hypogammaglobulinemia
  • You must not have had a serious systemic or local infection within 12 weeks prior to entry into the study
  • You must not have been exposed to a within 12 weeks prior to entry into the study, or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study
  • You must not have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB
  • You must not have a serious and/or unstable illness that, in the opinion of the investigator, poses an unacceptable risk for the your participation in the study
  • You must not have or have had a history of lymphoproliferative disease; or signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or active primary or recurrent malignant disease; or been in remission from for less than 5 years
  • You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse within the last 2 years
  • You must not have donated blood of more than 500 mL within 4 weeks
  • You must not have received a topical Ps treatment within 2 weeks prior to entry into the study

    • Exceptions:
    • class 6 (mild, such as desonide) or class 7 (least potent, such as hydrocortisone) topical used on the face, axilla, palms, soles, and/or genitalia
    • non-medicated shampoos (for example, that do not contain corticosteroids, coal tar, or vitamin D3 analogues)
    • emollients that do not contain alpha or beta hydroxyl acids
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
271 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.

    Drug: Placebo

  • Experimental
    Baricitinib 2 mg

    Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.

    Drug: Baricitinib

  • Experimental
    Baricitinib 4 mg

    Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.

    Drug: Baricitinib

  • Experimental
    Baricitinib 8 mg

    Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.

    Drug: Baricitinib

  • Experimental
    Baricitinib 10 mg

    Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.

    Drug: Baricitinib

Interventions

  • DrugPlacebo

    Administered orally

  • Administered orally

    Also known as: LY3009104, INCB028050

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

    Time frame: Week 12

  2. Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

    Time frame: Week 24

  3. Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

    Time frame: Week 92

  4. Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.

    Time frame: Baseline Part A, Week 12

  5. Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.

    Time frame: Baseline Part A, Week 24

  6. Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.

    Time frame: Baseline Part D, Week 92

  7. Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline Part A, Week 12

  8. Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.

    Time frame: Baseline Part A, Week 24

  9. Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.

    Time frame: Baseline Part D, Week 92

  10. Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline Part A, Week 12

  11. Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Baseline Part A, Week 24

  12. Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Baseline Part D, Week 92

  13. Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12

    The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline Part A, Week 12

  14. Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24

    The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.

    Time frame: Baseline Part A, Week 24

  15. Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92

    The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.

    Time frame: Baseline Part D, Week 92

  16. Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

    The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline Part A, Week 12

  17. Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

    The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.

    Time frame: Baseline Part A, Week 24

  18. Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

    The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.

    Time frame: Baseline Part D, Week 92

  19. Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C

    Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score \>125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.

    Time frame: Week 40

  20. Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib

    Time frame: Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse

  21. PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)

    Time frame: Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse

07

Results

Posted Jul 18, 2017

Participant flow

Participant Psoriasis Area and Severity Index (PASI) score at the conclusion of Part A stratified participants as either Responder (PASI ≥75), Partial Responder (PASI 50 - PASI 74), or Non-Responder (PASI \<50).

Part A: Initial Treatment Period
Participant flow — Part A: Initial Treatment Period
MilestonePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo ExtensionPart C: Responder - Low Dose to PlaceboPart C: Responder - Low Dose to ½ Low DosePart C: Responder - High Dose to PlaceboPart C: Responder - High Dose to Low DosePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Started3432726469000000000000000
Received at least one dose of study drug3432726469000000000000000
Completed2728675552000000000000000
Not completed745917000000000000000
Withdrew: Adverse event00244000000000000000
Withdrew: Lack of efficacy31220000000000000000
Withdrew: Lost to follow-up00112000000000000000
Withdrew: Physician decision01010000000000000000
Withdrew: Sponsor decision20000000000000000000
Withdrew: Withdrawal by subject22012000000000000000
Withdrew: Discontinued at week 12 per protocol00009000000000000000
Part B: Extension or Step-Up Period
Participant flow — Part B: Extension or Step-Up Period
MilestonePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo ExtensionPart C: Responder - Low Dose to PlaceboPart C: Responder - Low Dose to ½ Low DosePart C: Responder - High Dose to PlaceboPart C: Responder - High Dose to Low DosePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Started00000296419165043800000000
Completed0000025511362522000000000
Not completed000004136102521800000000
Withdrew: Adverse event00000220023100000000
Withdrew: Lack of efficacy00000010131000000000
Withdrew: Lost to follow-up00000020010000000000
Withdrew: Physician decision00000010000000000000
Withdrew: Sponsor decision00000100000000000000
Withdrew: Withdrawal by subject00000010101200000000
Withdrew: Completed part b and not moving to partc0000016681916500000000
Part C: Washout or Step-Down Period
Participant flow — Part C: Washout or Step-Down Period
MilestonePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo ExtensionPart C: Responder - Low Dose to PlaceboPart C: Responder - Low Dose to ½ Low DosePart C: Responder - High Dose to PlaceboPart C: Responder - High Dose to Low DosePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Started000000000000151655550000
Completed00000000000010637180000
Not completed00000000000051018370000
Withdrew: Adverse event00000000000000220000
Withdrew: Lost to follow-up00000000000001000000
Withdrew: Withdrawal by subject00000000000000210000
Withdrew: Did not qualify for part d per protocol0000000000005914340000
Part D: Re-Treatment Period
Participant flow — Part D: Re-Treatment Period
MilestonePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo ExtensionPart C: Responder - Low Dose to PlaceboPart C: Responder - Low Dose to ½ Low DosePart C: Responder - High Dose to PlaceboPart C: Responder - High Dose to Low DosePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Started00000000000000003131937
Completed0000000000000000381230
Not completed00000000000000000577
Withdrew: Adverse event00000000000000000113
Withdrew: Death00000000000000000010
Withdrew: Lack of efficacy00000000000000000312
Withdrew: Lost to follow-up00000000000000000010
Withdrew: Physician decision00000000000000000011
Withdrew: Protocol violation00000000000000000010
Withdrew: Withdrawal by subject00000000000000000111

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
Percent of ParticipantsPart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])16.728.628.642.954.1
SecondaryPercentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
Percent of ParticipantsPart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])14.715.625.029.734.8
SecondaryPercentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

Time frame:
Week 24
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
Percent of ParticipantsPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])55.264.147.437.524.027.950.0
SecondaryPercentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.

Time frame:
Week 92
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
Percent of ParticipantsPart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])33.323.121.127.0
SecondaryChange From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.

Time frame:
Baseline Part A, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
Units on a ScalePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])5.14 ± 1.3709.40 ± 1.4139.46 ± 0.94111.52 ± 0.99713.93 ± 0.962
SecondaryChange From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.

Time frame:
Baseline Part A, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])
Units on a ScalePart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])15.62 ± 5.48016.69 ± 7.39912.94 ± 6.71112.23 ± 7.51014.55 ± 10.49313.67 ± 9.96613.43 ± 5.599
SecondaryChange From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.

Time frame:
Baseline Part D, Week 92
Reported as:
Mean · Units on a Scale
Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
Units on a ScalePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])6.33 ± 2.8363.25 ± 4.4475.84 ± 5.5446.98 ± 6.456
SecondaryChange From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline Part A, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12
Units on a ScalePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12-1.7 ± 0.98-3.4 ± 1.00-4.6 ± 0.67-4.0 ± 0.71-5.1 ± 0.69
SecondaryChange From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.

Time frame:
Baseline Part A, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24
Units on a ScalePart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24-6.9 ± 7.53-7.0 ± 8.18-3.8 ± 6.27-1.5 ± 5.92-7.8 ± 6.89-4.5 ± 8.99-3.5 ± 11.76
SecondaryChange From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.

Time frame:
Baseline Part D, Week 92
Reported as:
Mean · Units on a Scale
Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92
Units on a ScalePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92-3.3 ± 4.93-0.5 ± 3.62-2.1 ± 7.40-5.0 ± 6.31
SecondaryChange From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline Part A, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12
Units on a ScalePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12-1.1 ± 0.48-2.8 ± 0.49-3.3 ± 0.33-3.8 ± 0.35-4.7 ± 0.34
SecondaryChange From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Baseline Part A, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24
Units on a ScalePart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24-4.7 ± 3.52-5.6 ± 2.96-5.4 ± 3.83-3.4 ± 3.69-4.1 ± 3.33-3.5 ± 3.03-2.5 ± 4.11
SecondaryChange From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Baseline Part D, Week 92
Reported as:
Mean · Units on a Scale
Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92
Units on a ScalePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92-2.3 ± 0.58-2.5 ± 3.23-2.7 ± 2.91-3.1 ± 3.38
SecondaryChange From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12

The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline Part A, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12
Units on a ScalePart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12-0.9 ± 0.57-1.0 ± 0.58-1.0 ± 0.39-0.7 ± 0.40-0.9 ± 0.40
SecondaryChange From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24

The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.

Time frame:
Baseline Part A, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24
Units on a ScalePart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24-1.6 ± 2.48-2.6 ± 3.80-1.4 ± 3.15-1.2 ± 2.67-1.6 ± 2.99-2.2 ± 4.64-3.0 ± 6.16
SecondaryChange From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92

The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.

Time frame:
Baseline Part D, Week 92
Reported as:
Mean · Units on a Scale
Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92
Units on a ScalePart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92—-0.25 ± 1.708-0.13 ± 3.796-0.86 ± 2.143
SecondaryChange From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline Part A, Week 12
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
Millimeter (mm)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mg
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores2.9 ± 2.555.7 ± 2.466.4 ± 1.629.5 ± 1.717.8 ± 1.69
SecondaryChange From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.

Time frame:
Baseline Part A, Week 24
Reported as:
Mean · mm
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
mmPart B: Responder - Low DosePart B: Responder - High DosePart B: Partial- and Non-responder - Placebo to High DosePart B: Partial-responder - Low Dose to Low DosePart B: Partial- and Non-responder - Low Dose to High DosePart B: Partial- and Non-responder - High Dose to High DosePart B: Placebo Extension
Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores8.1 ± 11.4113.2 ± 22.069.6 ± 10.789.4 ± 20.957.5 ± 14.4710.5 ± 19.947.8 ± 11.92
SecondaryChange From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores

The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the "worst health you can imagine" and 100 mm indicated the "best health you can imagine". This information is used as a quantitative measure of health outcome.

Time frame:
Baseline Part D, Week 92
Reported as:
Mean · mm
Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores
mmPart D: Baricitinib 2 mg - RetreatmentPart D: Baricitinib 4 mg - RetreatmentPart D: Baricitinib 8 mg - RetreatmentPart D: Baricitinib 10 mg - Retreatment
Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores8.67 ± 10.2634.00 ± 26.9204.78 ± 13.5714.19 ± 19.727
SecondaryPercentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C

Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score \>125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C
Percentage of ParticipantsPart C: Responder - Low Dose to PlaceboPart C: Responder - Low Dose to ½ Low DosePart C: Responder - High Dose to PlaceboPart C: Responder - High Dose to Low Dose
Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C0000
SecondaryPharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
Time frame:
Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse
Reported as:
Geometric mean · nanomole (nM)
Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
nanomole (nM)Baricitinib 2 mgBaricitinib 4 mgBaricitinib 8 mgBaricitinib 10 mg
Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib52.4 ± 24.7106 ± 25.9222 ± 24.4260 ± 22.9
SecondaryPK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)
Time frame:
Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse
Reported as:
Geometric mean · nanomole*hour (nM*h)
PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)
nanomole*hour (nM*h)Baricitinib 2 mgBaricitinib 4 mgBaricitinib 8 mgBaricitinib 10 mg
PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)462 ± 40.7975 ± 41.12030 ± 43.32440 ± 42.2

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo—1/34 (2.9%)11/34 (32.4%)
Part A: Baricitinib 2 mg—1/32 (3.1%)9/32 (28.1%)
Part A: Baricitinib 4 mg—1/72 (1.4%)12/72 (16.7%)
Part A: Baricitinib 8 mg—1/64 (1.6%)21/64 (32.8%)
Part A: Baricitinib 10 mg—1/69 (1.4%)23/69 (33.3%)
Part B: Placebo—0/8 (0%)4/8 (50%)
Part B: Low Dose—0/45 (0%)13/45 (28.9%)
Part B: High Dose—2/176 (1.1%)41/176 (23.3%)
Part C: Placebo—1/70 (1.4%)11/70 (15.7%)
Part C: Baricitinib—1/71 (1.4%)16/71 (22.5%)
Part D: All Baricitinib Doses—1/72 (1.4%)37/72 (51.4%)
Follow-up: Always Placebo—0/8 (0%)0/8 (0%)
Follow-up: Ever Used Baricitinib—0/185 (0%)8/185 (4.3%)
Most frequent serious events
Most frequent serious events
EventPart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: PlaceboPart B: Low DosePart B: High DosePart C: PlaceboPart C: BaricitinibPart D: All Baricitinib DosesFollow-up: Always PlaceboFollow-up: Ever Used Baricitinib
Ovarian adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/340/320/720/640/690/80/450/1760/701/170/720/80/185
PsoriasisSkin and subcutaneous tissue disorders0/341/320/720/640/690/80/450/1760/700/710/720/80/185
Diabetic footSkin and subcutaneous tissue disorders1/340/320/720/640/690/80/450/1760/700/710/720/80/185
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/340/320/721/640/690/80/450/1760/700/710/720/80/185
PneumoniaInfections and infestations0/340/320/720/641/690/80/450/1760/700/710/720/80/185
CellulitisInfections and infestations0/340/320/720/640/690/80/450/1761/700/710/720/80/185
Arteriosclerosis coronary arteryCardiac disorders0/340/320/720/640/690/80/450/1760/700/711/720/80/185
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/340/321/720/640/690/80/450/1760/700/710/720/80/185
Gastrointestinal haemorrhageGastrointestinal disorders0/340/320/720/640/690/80/451/1760/700/710/720/80/185
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/340/320/720/640/690/80/451/1760/700/710/720/80/185
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPart A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgPart B: PlaceboPart B: Low DosePart B: High DosePart C: PlaceboPart C: BaricitinibPart D: All Baricitinib DosesFollow-up: Always PlaceboFollow-up: Ever Used Baricitinib
NasopharyngitisInfections and infestations4/341/322/726/646/690/85/459/1763/706/7112/720/82/185
Gastric ulcerGastrointestinal disorders0/340/320/720/640/691/80/450/1760/700/710/720/80/185
Muscle strainInjury, poisoning and procedural complications0/340/320/721/640/691/80/452/1760/700/712/720/80/185
Joint swellingMusculoskeletal and connective tissue disorders0/340/320/720/641/691/80/450/1760/700/710/720/80/185
HeadacheNervous system disorders2/340/323/725/641/691/83/457/1761/701/711/720/80/185
Upper respiratory tract infectionInfections and infestations1/341/320/721/642/690/82/455/1760/701/717/720/81/185
PregnancyPregnancy, puerperium and perinatal conditions0/340/320/720/640/690/81/130/1760/700/710/720/80/185
Blood creatine phosphokinase increasedInvestigations0/342/321/723/645/690/80/451/1760/701/713/720/81/185
Abdominal discomfortGastrointestinal disorders1/342/320/722/642/690/80/450/1760/700/710/720/80/185
FatigueGeneral disorders1/342/320/721/640/690/80/451/1760/700/711/720/80/185

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Customized
Age, Customized(Years)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Mean46.70 ± 15.14447.81 ± 15.16547.21 ± 11.65047.37 ± 15.82947.43 ± 10.42547.31 ± 13.268
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Female11918181874
Male2323544651197
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Hispanic or Latino4611121043
Not Hispanic or Latino3026615259228
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
American Indian or Alaska Native000101
Asian761291145
Native Hawaiian or Other Pacific Islander000000
Black or African American101147
White2626585253215
More than one race000112
Unknown or Not Reported001001
Region of Enrollment
Region of Enrollment(Participants)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Japan4498833
North America3028635661238
Duration of Psoriasis (Ps)
Duration of Psoriasis (Ps)(Years)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Mean16.42 ± 14.29715.00 ± 9.95119.90 ± 12.76616.56 ± 11.94816.60 ± 10.65317.26 ± 11.995
Percent Body Surface Area (BSA) Affected by Psoriasis
Percent Body Surface Area (BSA) Affected by Psoriasis(Percent of BSA)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Mean23.18 ± 11.89030.78 ± 20.52328.61 ± 18.79728.23 ± 15.72624.45 ± 12.07927.04 ± 16.101
Baseline Psoriasis Area and Severity Index (PASI) Score
Baseline Psoriasis Area and Severity Index (PASI) Score(Units on a Scale)Part A: PlaceboPart A: Baricitinib 2 mgPart A: Baricitinib 4 mgPart A: Baricitinib 8 mgPart A: Baricitinib 10 mgTotal
Mean19.06 ± 6.80521.36 ± 11.05620.58 ± 9.43820.24 ± 7.82719.01 ± 6.17720.00 ± 8.228
08

Study locations

35 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Monica, California 90404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33175, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miramar, Florida 33027, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ocala, Florida 34471, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alpharetta, Georgia 30022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington Heights, Illinois 60005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    East Windsor, New Jersey 08520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14623, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Exton, Pennsylvania 19341, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78705, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kelowna, British Columbia V1Y 4X3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Surrey, British Columbia V3R 6A7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peterborough, Ontario K9J 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond Hill, Ontario L4B 1A5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterloo, Ontario N2J 1C4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1H1Z1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Quebec, G1V4X7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 292-8535, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 814-0180, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ishikawa, 923-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 2308765, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 545-8586, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 350-0495, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tochigi, 329- 0498, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 162-8543, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toyama, 9330871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carolina, 00985, Puerto Rico
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2012 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 4 years 7 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2011
First posted
Dec 13, 2011
Start
Dec 2011
Primary completionActual
Dec 2012
CompletionActual
Aug 2014
Results delay requested
Jan 11, 2013
Results first posted
Jul 18, 2017
Last update
Sep 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01490632
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Dec 13, 2011
Start date
Dec 2011
Primary completion
Dec 2012
Completion
Aug 2014
Results posted
Jul 18, 2017
Last update
Sep 27, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion